En trivelig.dag for Navamedic:


Navamedic is pleased to announce that it has won the tender for the entire
Norwegian market for four major antibiotics for the period from February 2022 to
February 2024. The winning factors were environmental aspects and user
friendliness. This tender will secure a substantial amount of the projected
sales volumes for the Navamedic antibiotics portfolio through 2023.

"We are pleased to win our first antibiotics tender and delighted to see that
our focus on environmental aspects and user friendliness has paid off," says
Kathrine Gamborg Andreassen, CEO of Navamedic. "Together with our partner and
shareholder, ACS Dobfar, we have invested in state-of-the-art environmental
documentation and user friendly packaging".